Article

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Osimertinib

2022-08-23

Abstract excerpt

<h4>Background: </h4> Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) in 2015 for treatment of non-small cell lung cancer (NSCLC). Our study was to explore the adverse events (AEs) caused by osimertinib through data mining of the US FDA Adverse Event Reporting System (FAERS), and prov...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 12becf6d-042f-5d62-9190-97fdceef4a19
DOI: 10.21203/rs.3.rs-1945568/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibDOI 10.21203/rs.3.rs-1945568/v1Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databasesSemantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.Semantic proximity Read

Real-world safety profile of Enfortumab Vedotin: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read

Pharmacovigilance analysis of inclisiran:a real-world assessment based on the FAERS databaseSemantic proximity Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read

Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.Semantic proximity Read

Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance StudySemantic proximity Read